NanoViricides Inc. (NNVC)

[Ubertino]

--a major research institute in New York has approved an investigator-initiated in vivo study which will evaluate certain topical nanoviricide(TM) eye drug candidates. This approved project is designed to study the effect of different nanoviricide(TM) drug candidates on herpes simplex virus (HSV) infection of the cornea. The Company will be providing the drug candidates free of charge. The principal investigator is an Associate Professor of Ophthalmology at the Albert Einstein School of Medicine. She has previously conducted an in vivo study that resulted in the demonstration of a strong clinical effect of certain nanoviricide drug candidates against adenovirus induced keratoconjunctivitis in rabbit eyes.--

So it's not REPEAT and CONFIRM as much as WIDEN to include a herpes simplex virus investigation.

I take from that that this investigator was very pleased with the previous results and now wants to verify that HSV infection can be countered as well.

Baby steps! The FDA is watching.